Synthetic liposomal nanoparticles comprising a cell-free transcription and translation machinery, a plasmid encoding a cytokine, and a regulatable caged ATP molecule, as well as microparticles encasing the synthetic liposomal nanoparticles and methods of making and using the synthetic liposomal nanoparticles, are described herein. These liposomal nanoparticles may be used for the controlled release o a cytokine within a localized environment of, for example a tumor, as part of a therapeutic treatment of cancer, or for localized treatment at a focus of interest of an autoimmune disease, an allergic reaction or hypersensitivity reaction, a localized site of an infection or infectious disease, a localized site of an injury or other damage, a transplant or other surgical site, or a blood clot. Further, microparticles produced by encapsulating hundreds of liposomal nanoparticles, and their therapeutic uses, are also described.

Disclosed herein are a method for producing a miniaturized liposome on a large production scale, and an apparatus for producing a liposome which is to be used in the above-mentioned method. Provided is a method for producing a liposome, including a step of stirring a mixture containing an oil phase in which at least one lipid is dissolved in an organic solvent and a water phase in a first tank of an apparatus having the first tank and a circulation path, in which the ratio of the capacity of the circulation path to the total capacity of the tank and the circulation path is 0.4 or less and/or the time required for the mixture to return to the first tank after being discharged therefrom is within 2.0 minutes.

A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment.

The present invention relates to a method for producing extracellular vesicles (EV) in large quantities by using a peptide derived from Noxa protein that plays a key role in apoptosis and derivatives thereof, and the use of the peptide for promoting extracellular vesicle production and the method for producing extracellular vesicles by using the same of the present invention can efficiently and uniformly mass-produce extracellular vesicles, and can produce extracellular vesicles which load drugs passing poorly through cellular membranes as well as recombinant proteins or plasmid DNA.

An aqueous, intra-oral, nanoemulsion blend is provided that enhances mitochondrial performance in mammals when orally administered. The blend includes at least two different monolayer surfactant bound particle components and at least one bilayer water-core liposome component. The blend optionally may include a micelle.

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading is capability retained. The process is scalable and the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and predictable drug retention when the liposome encapsulated drug is administered in patients.

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

According to some embodiments, the present invention provides compositions and methods for making and using multifunctional polymerized liposomes finding relevant application in medical sciences, particularly in bioimaging, diagnostics, drug delivery, and drug formulation. The compositions and methods involve lipids that are both polymerizable and have a “clickable” group that provides the ability to functionalize via a click reaction with various functional moieties useful for the above-listed applications.

A group of inventions relates to pharmaceutics and refers to a method for preparing a liposomal composition and a pharmacologically active liposomal composition for ophthalmotherapy prepared by this method. The method is implemented by creating a mixture of solutions of latanoprost, egg phosphatidylcholine and cholesterol in organic solvents, vacuum drying thereof, emulsifying in an aqueous medium, and dispersing an emulsion under pressure. According to the invention, a solution of dipalmytoyl phosphatidylglycerol is introduced into the mixture of solutions, wherein latanoprost, egg phosphatidylcholine, and cholesterol are dissolved in ethyl alcohol, while dipalmytoyl phosphatidylglycerol is dissolved in a mixture of ethyl alcohol and chloroform. The emulsifying of the dried mixture is conducted by a lactose solution in a pH 7.1 buffer, while the dispersing of the emulsion is conducted at a stepwise pressure increase from 300 to 800 at followed by a sterilizing filtration and a freeze drying.

The composition prepared by this method is a frozen-dried powder and a formulation thereof comprises:

TABLE-US-00001 Latanoprost 1, Egg phosphatidylcholine 20.0-30.0, Dipalmytoyl  0.6-0.75, phosphatidylglycerol Cholesterol 0.5-0.9, Lactose 40.0-60.0, Water residue the remainder.

The pharmacologically active liposomal composition has a prolonged antihypertensive and neuroprotective action in case of ocular hypertension and glaucoma, and it is suitable for preparation a solution for an instillation use and/or injectable subconjunctival administration.

2 ind.cls., 2 d.cls.

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.